Core Viewpoint - The announcement indicates that Jiuzhitang's subsidiary Youbo Pharmaceutical has initiated a Phase II clinical trial for the new drug YB211, which targets acute bacterial skin and skin structure infections caused by Gram-positive pathogens [1] Group 1: Clinical Trial Details - The clinical trial kickoff meeting was held on May 24, 2025, with 26 clinical trial centers, including Fudan University Huashan Hospital [1] - YB211 is a novel cyclic lipopeptide with a new chemical structure, and the trial will compare its efficacy against the control drug Daptomycin in adult patients [1] - The trial consists of two parts: dose exploration and pharmacokinetic studies [1] Group 2: Regulatory Approvals - Youbo Pharmaceutical received the clinical trial approval notice from the National Medical Products Administration on February 6, 2025 [1] - The company obtained the ethics review committee's approval by the end of April [1] Group 3: Impact on Company Performance - The initiation of the clinical trial is expected to advance the research and evaluation progress of the new drug YB211 [1] - However, it is noted that there will be no significant impact on the company's operating performance in the short term [1]

公告文件 证券代码：000989 证券简称：九芝堂 公告编号：2025-045 九芝堂股份有限公司 关于对深圳证券交易所 2024 年年报问询函回复的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈 述或重大遗漏。 九芝堂股份有限公司（以下简称"公司"、"本公司"）前期已收到并回复深圳 证券交易所《关于对九芝堂股份有限公司 2024 年年报的问询函》，本公司现将 回函情况公告如下： "公司""本公司""九芝堂"：九芝堂股份有限公司 "博搏医药"：牡丹江博搏医药有限责任公司 "友搏药业"：牡丹江友搏药业有限责任公司 "成都九芝堂"：成都九芝堂金鼎药业有限公司 "迪龙制药"：黑龙江迪龙制药有限公司 "并购基金"：珠海横琴九芝堂雍和启航股权投资基金（有限合伙） "九芝堂医药"：湖南九芝堂医药有限公司 "Stemedica"：Stemedica Cell Technologies Inc. 一、公司近年业绩持续下滑。年报显示，2022 年至 2024 年，你公司实现营 业收入分别为 30.33 亿元、29.61 亿元和 23.71 亿元，归母净利润分别为 3.58 亿 元、2.9 ...

Group 1 - As of May 16, three ST companies, *ST Aonong, ST Muyao, and *ST Kexin, announced the removal of their ST labels, bringing the total number of companies that have "un-capped" this year to over 20 [1] - In April and May, three listed companies from Hunan successfully removed their ST labels, with two more applying for the same [1] - The three Hunan companies that successfully "un-capped" are Bubugao, Jiuzhitang, and Youkeshu [1] Group 2 - ST Bubugao successfully "un-capped" on April 21, attributed to successful restructuring and the introduction of the Pang Donglai model, enhancing its competitive advantage [1] - ST Bubugao's fresh product category gross margin increased to 22%, exceeding the industry average by 15 percentage points, and its unique brand ratio in shopping centers is expected to reach 31% by 2024 [1] - For Q1 2025, ST Bubugao reported earnings per share of 0.04 yuan and a net profit of 119.04 million yuan, with a year-on-year growth rate of 488.44% [1] Group 3 - ST Jiuzhitang successfully "un-capped" on May 7, focusing on the production and sales of hepatitis and blood supplement series drugs [2] - The company rectified internal control deficiencies that led to a negative audit opinion last year, and announced a cash dividend of 3 yuan per 10 shares, totaling 250 million yuan [2] Group 4 - *ST Youkeshu completed its restructuring and changed its name to "Youkeshu," focusing on B2C cross-border e-commerce [2] - The company reported a debt restructuring gain of 210 million yuan, with a net profit of 17,290 yuan for Q1 2025, reflecting a year-on-year growth rate of 105.80% [2] Group 5 - *ST Kaiyuan announced a cash asset donation of 230 million yuan from an affiliate, leading to a positive net asset position by the end of 2024 [3] - *ST Jingfeng is in the pre-restructuring phase and has applied to remove its delisting risk warning after achieving a positive net asset position for 2024 [3]

A股创新药板块拉升，哈三联涨停，万邦医药涨超10%，九芝堂、科伦药业、凯莱英纷纷拉升。 ...

暗盘资金正涌入这些股票，点击速看>>> 创新药板块拉升，哈三联（002900）涨停，万邦医药（301520）涨超10%，九芝堂（000989）、科伦药 业（002422）、凯莱英（002821）纷纷拉升。 ...

除了*ST有树，5月以来，九芝堂、山东墨龙、理工导航、天邦食品等11家上市公司宣布股 票撤销ST、*ST。其中，4家公司实现"脱帽"，撤销ST；仅ST宁科是"摘星"，由*ST变为 ST；恒宇信通、新宁物流、文投控股等6家公司"摘星脱帽"，撤销*ST。 *ST有树5月11日晚间发布公告称，公司股票交易将于5月13日（星期二）开市起撤销退市 风险警示及其他风险警示，股票简称由"*ST有树"变更为"有棵树"。公司股票将于5月12日 （星期一）开市起停牌1天，并于5月13日（星期二）开市起复牌。 对此，利安达事务所出具的《2024年年度审计报告》与《关于有棵树科技股份有限公司 2024年度财务报告非标准审计意见的专项说明》显示，公司持续经营能力存在不确定性的 情形已消除。 公告称，关于撤销对公司股票交易退市风险警示及其他风险警示的申请已获得深圳证券交易 所审核同意。 5月以来11家公司股票 撤销ST、*ST 今年以来，成功"摘星脱帽"的公司不在少数。 Wind数据显示，剔除退市股，今年以来截至5月11日18时，21家A股上市公司撤销ST、 *ST。其中，有7家ST公司实现"脱帽"；2家公司实现"摘星"，由*ST变为S ...

| 代码 | 简称 | 今日涨跌幅 | 今日换手率 | 主力资金流量（万 | 主力资金净流入比率 | | --- | --- | --- | --- | --- | --- | | | | （%） | （%） | 元） | （%） | | 300740 | 水羊股 份 | 7.34 | 11.92 | 1365.96 | 2.37 | | 002762 | *ST金 比 | 1.87 | 6.12 | 764.00 | 12.09 | | 002172 | 澳洋健 康 | -1.64 | 5.20 | 490.76 | 3.40 | | 600572 | 康恩贝 | 0.00 | 0.81 | 453.06 | 4.92 | | 002566 | 益盛药 业 | 0.56 | 2.84 | 449.27 | 9.45 | | 000516 | 国际医 学 | -2.10 | 1.02 | 173.25 | 1.49 | | 603139 | 康惠制 | -1.57 | 1.79 | -62.03 | -1.77 | | | 药 | | | | | | 000615 | *ST 美 | 0.63 | 1.59 ...

Group 1: Company Performance and Financials - In 2024, the company achieved operating revenue of 2.371 billion yuan and a net profit attributable to shareholders of 216 million yuan, with cash flow from operating activities increasing by 83.14% to 199 million yuan [2] - The company aims to maintain high-quality development despite challenges from rising raw material prices, focusing on product-centric strategies and diversifying its product portfolio [2][3] Group 2: Innovation and R&D - The company is actively developing its stem cell research, with ongoing clinical trials for treatments related to ischemic stroke and autoimmune diseases, having enrolled 31 and 8 participants respectively [3] - A GMP-compliant stem cell R&D production base has been established, meeting both Chinese and U.S. drug application standards, and the company has received CNAS certification [3] Group 3: Shareholder Returns - The company announced a cash dividend of 3 yuan per 10 shares for the 2024 fiscal year, with the dividend record date on May 7 and payment on May 8 [4] - Cumulatively, the company has distributed over 4 billion yuan in dividends since its listing [5] Group 4: Corporate Governance - In January, the company underwent a change in control, with the Heilongjiang Provincial State-owned Assets Supervision and Administration Commission becoming the new actual controller, which is expected to enhance operational efficiency and market competitiveness [6]

Summary of Key Points Core Insights - The report highlights various companies undergoing temporary suspensions of trading due to different reasons, including financial disclosures and potential delisting risks. This indicates a volatile market environment where investor confidence may be affected by such events [2][3][4]. Company Specifics - ST Jiuzhi (000989) announced a temporary suspension of trading on May 6, 2025, due to the cancellation of other risk warnings [2]. - In the case of ST Gongzhi (000584), trading was suspended due to a risk warning regarding potential delisting, effective from April 28, 2025 [2]. - ST Hengli (000622) and Tianmao Group (000627) also faced trading suspensions due to their inability to disclose periodic reports within the legal timeframe, effective from May 6, 2025 [2]. - Binhai Energy (000695) is undergoing a trading suspension as it plans to issue shares for asset acquisition and raise matching funds, effective from April 30, 2025 [2]. - Electric Power Investment Energy (002128) is also suspended for similar reasons related to asset acquisition and related party transactions, effective from May 6, 2025 [2]. Industry Context - The report reflects a broader trend in the market where companies are facing increased scrutiny and regulatory challenges, leading to trading suspensions. This could signal potential investment risks in the affected sectors [2][3][4].

证券代码：000989 证券简称：ST九芝 公告编号：2025-044 九芝堂股份有限公司 公告文件 关于撤销其他风险警示暨停复牌的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈 述或重大遗漏。 特别提示： 1、九芝堂股份有限公司（以下简称"公司"）股票交易于 2025 年 5 月 6 日 停牌一天，于 2025 年 5 月 7 日开市起复牌。 2、公司股票自 5 月 7 日开市起撤销其他风险警示，证券简称由 "ST 九芝" 变更为"九芝堂"，证券代码仍为"000989"，撤销其他风险警示后，公司股票交 易日的涨跌幅限制由 5%变更为 10% 。 一、股票种类、简称、证券代码、涨跌幅以及股票停复牌安排 1、股票种类：人民币普通股； 2、股票简称：由"ST 九芝"变更为"九芝堂"； 3、证券代码：仍为"000989"； 4、撤销其他风险警示的起始日：2025 年 5 月 7 日； 5、公司股票停复牌安排：公司股票将于 2025 年 5 月 6 日停牌一天，并于 2025 年 5 月 7 日开市起复牌； 公告文件 出具无法表示意见或者否定意见的内部控制审计报告或者鉴证报告， ...